Overview

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
GLP-1 increases skeletal and cardiac microvascular perfusion and improves insulin's microvascular responses in human subjects with T1DM, leading to improved metabolic insulin responses, endothelial function, and increased muscle oxygenation
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Virginia
Collaborators:
American Diabetes Association
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Glucagon
Glucagon-Like Peptide 1
Insulin
Insulin, Globin Zinc